<DOC>
	<DOC>NCT02636595</DOC>
	<brief_summary>The purpose of this study is to evaluate the effect of response to treatment by evaluating the percentage of subjects achieving a 12-week sustained virologic response (SVR12) after 12 weeks of treatment with ABT-493/ABT-530 and to evaluate the safety of the regimen in participants with chronic hepatitis C virus (HCV) genotype (GT) 4, 5, or 6 infection.</brief_summary>
	<brief_title>The Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 4, 5, or 6 Infection (ENDURANCE-4)</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<criteria>1. Screening laboratory result indicating HCV GT4, 5, or 6 infection. 2. Chronic HCV infection. 3. HCV treatmentna√Øve or treatment experienced (IFN or pegIFN with or without RBV; SOF plus RBV with or without pegIFN). 4. Noncirrhotic participants. 1. History of severe, lifethreatening or other significant sensitivity to any excipient of the study drugs. 2. Female who is pregnant, planning to become pregnant during the study, or breastfeeding; or male whose partner is pregnant or planning to become pregnant during the study. 3. Recent (within 6 months prior to study drug administration) history of drug or alcohol abuse that could preclude adherence to the protocol in the opinion of the investigator. 4. Positive test result at Screening for hepatitis B surface antigen (HBsAg) or antihuman immunodeficiency virus antibody (HIV Ab). 5. Coinfection with more than one HCV genotype.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Hepatitis C Genotype 4</keyword>
	<keyword>Hepatitis C</keyword>
	<keyword>Chronic Hepatitis C</keyword>
	<keyword>Hepatitis C Genotype 6</keyword>
	<keyword>Hepatitis C Genotype 5</keyword>
</DOC>